CCND1 and melanoma: Esculetin alleviates drug resistance by downregulating cyclin D1 in breast cancer (CMT‐U27, CF41.mg),38 colon cancer (HCT‐116 cell),45 leukemia (HL‐60),60 melanoma (G361 cell),24 and renal cancer (786‐O and SN12‐PM6 cell).26